AKTX
Akari Therapeutics Plc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 11-15-2018 | 08-17-2018 | 03-21-2018 | 11-13-2017 | 08-10-2017 | 05-15-2017 | |
|---|---|---|---|---|---|---|
| Actual EPS | -0.04 | -0.28 | -0.07 | -0.09 | -0.06 | -0.09 |
| Consensus EPS | -1.0 | -0.7 | -0.54 | |||
| Estimated EPS | -1.0 | -0.7 | -0.54 | |||
| Number of Estimates | 1 | 1 | 1 | |||
| EPS Surprise | $0.91 | $0.64 | $0.45 |
Stats
Summary
Akari Therapeutics PLC is a biopharmaceutical company in clinical stage. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system.
Market Cap: 48.7 Million
Primary Exchange: NASDAQ Capital Market
Website: http://www.akaritx.com
Shares Outstanding: 15.3 Million
Float: 13.9 Million
Dividend: 0.0 (0.0%)
Beta: -8.834261
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 597 Thousand
Ethical Flags
Longest drawdown: 1286 trading days
From: 2014-01-15 To: 2019-02-20
Lowest Point:
Akari announces new Coversin data, key readouts expected next quarter
via: SeekingAlpha at 2018-11-30 16:40:56:000
Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) announces new data on lead candidate Coversin that it says underscores its differentiation. More news on: Akari Therapeutics Plc, Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Akari announces new Coversin data, key readouts expected next quarter
via: SeekingAlpha at 2018-11-30 16:40:56:000
Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) announces new data on lead candidate Coversin that it says underscores its differentiation. More news on: Akari Therapeutics Plc, Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Akari announces new Coversin data, key readouts expected next quarter
via: SeekingAlpha at 2018-11-30 16:40:56:000
Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) announces new data on lead candidate Coversin that it says underscores its differentiation. More news on: Akari Therapeutics Plc, Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Akari announces new Coversin data, key readouts expected next quarter
via: SeekingAlpha at 2018-11-30 16:40:56:000
Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) announces new data on lead candidate Coversin that it says underscores its differentiation. More news on: Akari Therapeutics Plc, Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Akari announces new Coversin data, key readouts expected next quarter
via: SeekingAlpha at 2018-11-30 16:40:56:000
Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) announces new data on lead candidate Coversin that it says underscores its differentiation. More news on: Akari Therapeutics Plc, Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Akari Therapeutics reports Q3 results
via: SeekingAlpha at 2018-11-15 06:52:13:000
Akari Therapeutics (NASDAQ: AKTX ): Q3 GAAP EPS of $0.00. More news on: Akari Therapeutics Plc, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Akari Therapeutics reports Q3 results
via: SeekingAlpha at 2018-11-15 06:52:13:000
Akari Therapeutics (NASDAQ: AKTX ): Q3 GAAP EPS of $0.00. More news on: Akari Therapeutics Plc, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Akari Therapeutics reports Q3 results
via: SeekingAlpha at 2018-11-15 06:52:13:000
Akari Therapeutics (NASDAQ: AKTX ): Q3 GAAP EPS of $0.00. More news on: Akari Therapeutics Plc, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Akari Therapeutics reports Q2 results
via: SeekingAlpha at 2018-09-27 06:59:19:000
Akari Therapeutics (NASDAQ: AKTX ): Q2 GAAP EPS of -$0.01. More news on: Akari Therapeutics Plc, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Akari Therapeutics reports Q2 results
via: SeekingAlpha at 2018-09-27 06:59:19:000
Akari Therapeutics (NASDAQ: AKTX ): Q2 GAAP EPS of -$0.01. More news on: Akari Therapeutics Plc, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Akari Therapeutics reports Q2 results
via: SeekingAlpha at 2018-09-27 06:59:19:000
Akari Therapeutics (NASDAQ: AKTX ): Q2 GAAP EPS of -$0.01. More news on: Akari Therapeutics Plc, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Ra Pharma's zilucoplan shows favorable PK profile in renal impairment patients, expanding potential clinical programs
via: SeekingAlpha at 2018-09-26 08:14:53:000
Results from a Phase 1b assessing the pharmacokinetics of Ra Pharmaceuticals' (NASDAQ: RARX ) RA101495 SC (zilucoplan) in patients with severe renal impairment showed a similar profile compared to healthy patients. There were no adverse events reported and the data indicate that no adjust… read more...
Premarket Gainers as of 9:05 am (09/12/2018)
via: SeekingAlpha at 2018-09-12 09:17:11:000
FOMX +31% as acne drug meets goals in late-stage trial. More news on: Foamix Pharmaceuticals, Galapagos, Bausch Health Companies Inc., Stocks on the move, , Read more … read more...
Premarket Gainers as of 9:05 am (09/12/2018)
via: SeekingAlpha at 2018-09-12 09:17:11:000
FOMX +31% as acne drug meets goals in late-stage trial. More news on: Foamix Pharmaceuticals, Galapagos, Bausch Health Companies Inc., Stocks on the move, , Read more … read more...
Premarket Gainers as of 9:05 am (09/12/2018)
via: SeekingAlpha at 2018-09-12 09:17:11:000
FOMX +31% as acne drug meets goals in late-stage trial. More news on: Foamix Pharmaceuticals, Galapagos, Bausch Health Companies Inc., Stocks on the move, , Read more … read more...
Akari Therapeutics net loss improves in Q1
via: SeekingAlpha at 2018-08-17 07:23:39:000
Akari Therapeutics ( AKTX ) Q1 results : Revenues: $0; R&D Expense: $1M (-83.3%); SG&A: $3.3M (+43.5%); Net Loss: ($1.3M) (+89.7%); Loss Per Share: $0.00; Quick Assets: $23.8M (-15.3%). More news on: Akari Therapeutics Plc, Healthcare stocks news, Earnings news and commentary, , … read more...
Akari Therapeutics net loss improves in Q1
via: SeekingAlpha at 2018-08-17 07:23:39:000
Akari Therapeutics ( AKTX ) Q1 results : Revenues: $0; R&D Expense: $1M (-83.3%); SG&A: $3.3M (+43.5%); Net Loss: ($1.3M) (+89.7%); Loss Per Share: $0.00; Quick Assets: $23.8M (-15.3%). More news on: Akari Therapeutics Plc, Healthcare stocks news, Earnings news and commentary, , … read more...
Akari Therapeutics net loss improves in Q1
via: SeekingAlpha at 2018-08-17 07:23:39:000
Akari Therapeutics ( AKTX ) Q1 results : Revenues: $0; R&D Expense: $1M (-83.3%); SG&A: $3.3M (+43.5%); Net Loss: ($1.3M) (+89.7%); Loss Per Share: $0.00; Quick Assets: $23.8M (-15.3%). More news on: Akari Therapeutics Plc, Healthcare stocks news, Earnings news and commentary, , … read more...
Akari Therapeutics net loss improves in Q1
via: SeekingAlpha at 2018-08-17 07:23:39:000
Akari Therapeutics ( AKTX ) Q1 results : Revenues: $0; R&D Expense: $1M (-83.3%); SG&A: $3.3M (+43.5%); Net Loss: ($1.3M) (+89.7%); Loss Per Share: $0.00; Quick Assets: $23.8M (-15.3%). More news on: Akari Therapeutics Plc, Healthcare stocks news, Earnings news and commentary, , … read more...
Akari Therapeutics net loss improves in Q1
via: SeekingAlpha at 2018-08-17 07:23:39:000
Akari Therapeutics ( AKTX ) Q1 results : Revenues: $0; R&D Expense: $1M (-83.3%); SG&A: $3.3M (+43.5%); Net Loss: ($1.3M) (+89.7%); Loss Per Share: $0.00; Quick Assets: $23.8M (-15.3%). More news on: Akari Therapeutics Plc, Healthcare stocks news, Earnings news and commentary, , … read more...
Akari Therapeutics reports Q1 results
via: SeekingAlpha at 2018-08-17 07:04:03:000
Akari Therapeutics (NASDAQ: AKTX ): Q1 EPS of $0.00 More news on: Akari Therapeutics Plc, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Akari Therapeutics reports Q1 results
via: SeekingAlpha at 2018-08-17 07:04:03:000
Akari Therapeutics (NASDAQ: AKTX ): Q1 EPS of $0.00 More news on: Akari Therapeutics Plc, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Akari Therapeutics reports Q1 results
via: SeekingAlpha at 2018-08-17 07:04:03:000
Akari Therapeutics (NASDAQ: AKTX ): Q1 EPS of $0.00 More news on: Akari Therapeutics Plc, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Akari Therapeutics reports Q1 results
via: SeekingAlpha at 2018-08-17 07:04:03:000
Akari Therapeutics (NASDAQ: AKTX ): Q1 EPS of $0.00 More news on: Akari Therapeutics Plc, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Akari Therapeutics reports Q1 results
via: SeekingAlpha at 2018-08-17 07:04:03:000
Akari Therapeutics (NASDAQ: AKTX ): Q1 EPS of $0.00 More news on: Akari Therapeutics Plc, Earnings news and commentary, Healthcare stocks news, , Read more … read more...
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)
via: SeekingAlpha at 2018-05-31 09:04:00:000
This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)
via: SeekingAlpha at 2018-05-31 09:04:00:000
This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...
Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)
via: SeekingAlpha at 2018-05-31 09:04:00:000
This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...
Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space
via: SeekingAlpha at 2018-04-09 13:39:22:000
I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph… read more...
Achillion, Omeros, Ra Rx, Reata, Chemocentryx And Others In The IgA Nephropathy Space
via: SeekingAlpha at 2018-04-09 13:39:22:000
I began this article with the intent of an Achillion Pharmaceuticals ( ACHN ) focus. However, as I learned more about each of these 5 companies, I've decided to give an equal spotlight to each. I will preface the real reason for this renal-focused article is due to my own diagnosis of IgA neph… read more...
Akari Therapeutics' (AKTX) CEO David Solomon on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-03-21 14:56:03:000
Akari Therapeutics, Inc. (AKTX) Q4 2017 Earnings Conference Call March 21, 2018, 08:30 ET Executives Peter Vozzo - West Wicke Partners David Solomon - CEO Dov Elefant - CFO Analysts Tim Lugo - William Blair Madhu Kumar - B. Riley FBR Presentation Operator Good m… read more...
Akari Therapeutics' (AKTX) CEO David Solomon on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-03-21 14:56:03:000
Akari Therapeutics, Inc. (AKTX) Q4 2017 Earnings Conference Call March 21, 2018, 08:30 ET Executives Peter Vozzo - West Wicke Partners David Solomon - CEO Dov Elefant - CFO Analysts Tim Lugo - William Blair Madhu Kumar - B. Riley FBR Presentation Operator Good m… read more...
Akari Therapeutics reports Q4 results
via: SeekingAlpha at 2018-03-21 08:45:58:000
Akari Therapeutics ( AKTX ) Q4 results : Revenues: $0; R&D Expense: $7.1M (+7.6%); SG&A: $3.7M (+12.1%); Operating Loss: ($10.8M) (-9.1%); Net Loss: ($9.3M) (-12.0%); Loss Per Share: ($0.01); Quick Assets: $28.1M (-36.3%). More news on: Akari Therapeutics Plc, Healthcare stocks ne… read more...
Akari Therapeutics reports Q4 results
via: SeekingAlpha at 2018-03-21 08:45:58:000
Akari Therapeutics ( AKTX ) Q4 results : Revenues: $0; R&D Expense: $7.1M (+7.6%); SG&A: $3.7M (+12.1%); Operating Loss: ($10.8M) (-9.1%); Net Loss: ($9.3M) (-12.0%); Loss Per Share: ($0.01); Quick Assets: $28.1M (-36.3%). More news on: Akari Therapeutics Plc, Healthcare stocks ne… read more...
Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket
via: SeekingAlpha at 2018-03-15 07:30:55:000
Alexion Pharmaceuticals (NASDAQ: ALXN ) is up 11% premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH). More news on: Alexion Pharmaceuticals… read more...
Alexion's long-acting PNH candidate ALXN1210 on par with Soliris in late-stage study; shares up 11% premarket
via: SeekingAlpha at 2018-03-15 07:30:55:000
Alexion Pharmaceuticals (NASDAQ: ALXN ) is up 11% premarket on light volume in response to its announcement of successful results from a Phase 3 clinical trial assessing ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH). More news on: Alexion Pharmaceuticals… read more...
Alexion Ups Its Game With ALXN1210 SC
via: SeekingAlpha at 2018-02-20 12:23:05:000
Alexion Pharmaceuticals ( ALXN ) a biopharmaceutical company which markets the blockbuster drug Soliris, is near the end of its journey to develop an even better version of Soliris called ALXN1210. Both Soliris (eculizumab) and ALXN1210 are antibodies which bind the complement protein C5, whic… read more...
Alexion Ups Its Game With ALXN1210 SC
via: SeekingAlpha at 2018-02-20 12:23:05:000
Alexion Pharmaceuticals ( ALXN ) a biopharmaceutical company which markets the blockbuster drug Soliris, is near the end of its journey to develop an even better version of Soliris called ALXN1210. Both Soliris (eculizumab) and ALXN1210 are antibodies which bind the complement protein C5, whic… read more...
Premarket Gainers as of 9:05 am (02/06/2018)
via: SeekingAlpha at 2018-02-06 09:17:54:000
ARGS +12% on option for group of PD-1 inhibitors. More news on: Argos Therapeutics, Inc., Akari Therapeutics Plc, Lumentum Holdings Inc., Stocks on the move, Read more … read more...
Akari completes mid-stage study of Coversin in PNH; shares up 13% premarket
via: SeekingAlpha at 2018-02-06 08:02:54:000
Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) is up 13% premarket on light volume in response to its announcement of final results from an eight-subject 90-day open-label Phase 2 clinical trial, COBALT, evaluating lead candidate Coversin in patients with paroxysmal … read more...
Achillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value
via: SeekingAlpha at 2018-01-09 11:31:28:000
Background of the Company Achillion ( ACHN ) is a biopharmaceutical company specializing in discovering and developing small molecules for complement-mediated diseases. The complement system is a part of the human innate immune system and is believed to comprise three pathways - the alt… read more...
Apellis Pharmaceuticals: This Horse Is Lame
via: SeekingAlpha at 2018-01-09 09:38:15:000
The approval of any drug by the FDA is based on the concept of benefit/risk. Obviously, for a drug to get approved, those knowledgeable in the field must believe that the benefits of the drug outweigh the risks. This benefit/risk ratio is a moving target. The risk that a patient would find acc… read more...
Akari Therapeutics (AKTX) Investor Presentation - Slideshow
via: SeekingAlpha at 2017-12-11 12:15:32:000
The following slide deck was published by Akari Therapeutics Plc in conjunction with this Read more … read more...
Premarket Gainers as of 9:05 am
via: SeekingAlpha at 2017-12-11 09:09:30:000
More news on: Blueprint Medicines, Catalyst Inc., bluebird bio, Inc., Stocks on the move, Read more … read more...
Akari's Coversin successful in mid-stage PNH study
via: SeekingAlpha at 2017-12-08 16:39:08:000
A Phase 2 clinical trial, COBALT , assessing Akari Therapeutics' (NASDAQ: AKTX ) lead candidate Coversin in patients with paroxysmal nocturnal hemoglobinuria (PNH) met the primary endpoint of a statistically significant reduction in LDH (lactate dehydrogenase) to within 1.8x the upper lim… read more...
Biotech Forum Daily Digest: Our Take On MiMedx
via: SeekingAlpha at 2017-12-05 08:18:50:000
Today's public figures can no longer write their own speeches or books, and there is some evidence that they can't read them either . - Gore Vidal The biotech sector had a decent performance in the previous week as the overall market drifted up powered by strong economic reading… read more...
Midday Gainers / Losers
via: SeekingAlpha at 2017-10-18 12:41:41:000
Gainers: SPPI +47% . OPTT +44% . DRIO +33% . CGG +22% . VERI +20% . PTI +19% . CREE +18% . VIVE +16% . ISIG +15% . HEBT +15% . More news on: Spectrum Pharmaceuticals, Inc., Ocean Power Technologies, Inc., DarioHealth Corp., Stocks on the move, Read more… read more...
Akari prices ADS offering at $5; shares down 24%
via: SeekingAlpha at 2017-10-18 09:34:54:000
Akari Therapeutics ( AKTX -23.8% ) prices its public offering of 3.48M American Depositary Shares (ADSs) at $5 per ADS. Underwriters over-allotment is an additional 522K ADSs. Closing date is October 20. More news on: Akari Therapeutics Plc, Healthcare stocks news, Stocks on the move, … read more...
3 Potential Long Ideas From Today's Relative Volume Scan
via: SeekingAlpha at 2017-10-12 20:14:16:000
Running daily or weekly scans (depending on available time) is a great way to find current and future winners in the healthcare sector and other areas of the stock market. Whether looking at relative volume, insider buying, stocks making new highs, breaks above the 50-day moving average or oth… read more...
Midday Gainers / Losers
via: SeekingAlpha at 2017-10-11 12:40:50:000
Gainers: LBIX +84% . CASI +71% . SRNE +37% . WPCS +37% . AKTX +34% . RGSE +34% . AMMA +23% . HMNY +22% . FRSX +19% . PVG +20% . More news on: Leading Brands Inc, CASI Pharmaceuticals, Sorrento Therapeutics, Inc., Stocks on the move, Read more … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2015-09-17 | 10.0 | 1.0 | 10.0 |